← All trials
NCT03596866
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 15, 2018
- Primary completion
- Oct 29, 2021
- Completion date
- Sep 4, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 246
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Ariad PharmaceuticalsLead sponsor
- Ariad PharmaceuticalsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.